Affiliation:
1. Departement de Pharmacotoxicologie, Hôpital Avicenne, Bobigny, France.
Abstract
Pefloxacin pharmacokinetics and serum bactericidal activities (SBA) against Escherichia coli and Staphylococcus aureus were compared after intravenous infusion of either a single 800-mg dose or twice-daily 400-mg doses into 16 healthy volunteers. Plasma pefloxacin concentrations were measured for up to 60 h, and SBAs were determined 1, 12, and 24 h after the start of the infusion. The mean areas under the concentration-versus-time curve for plasma were not different (138 versus 136 h.mg/liter). The mean clearances, volumes of distribution, and half-lives were also comparable. The mean (+/- standard deviation) maximal concentration after the 800-mg infusion was 12.11 +/- 1.35 versus 6.51 +/- 0.73 mg/liter after the first 400-mg infusion and 7.42 +/- 0.76 mg/liter after the second 400-mg infusion. Mean trough concentrations at 24 h were significantly different: 2.77 +/- 0.63 (800 mg) versus 1.93 +/- 0.49 (400 mg twice) mg/liter (P = 0.0007). Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h). Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1/16 (12 h), and 1/8 (24 h). Mean SBAs at 1 and 12 h were significantly higher after the 800-mg infusion than after the 400-mg infusion but were similar at 24 h for both regimens. Comparison of SBAs according to National Committee for Clinical Laboratory Standards criteria showed a similar adequacy at 24 h for both regimens against both strains. Administration of 800 mg of pefloxacin once a day is bioequivalent to 400 mg twice a day, and bactericidal activity of the 800-mg infusion is not less than that of two 400-mg infusions.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference23 articles.
1. Multiple dose ciprofloxacin kinetics in normal subjects;Aronoff G. E.;Clin. Pharmacol. Ther.,1984
2. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans;Barre J.;J. Pharm. Sci.,1984
3. Beaucaire G. 0. Leroy C. Beuscart P. Karps C. Chidiac and M. Caillaux. 1991. Clinical and bacteriological efficacy and practical aspects of amikacin given once daily for severe infections. J. Antimicrob. Chemother. 27(Suppl. C):91-103.
4. Courvalin P. F. W. Goldstein A. Philippon and J. Sirot. 1985. L'antibiogramme p. 191-192. Mpc Videom Paris.
5. Bactericidal activity of pefloxacin in combination with rifampin, fosfomycin and vancomycin against Staphylococcus aureus: determination by a dynamic method;Drugeon H. B.;Rev. Infect. Dis.,1988
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献